GWPH GW Pharmaceuticals Plc

156.79
+0.92  (+1%)
Previous Close 155.87
Open 155.9
Price To Book 7.11
Market Cap 4794436862
Shares 30,579,418
Volume 178,301
Short Ratio
Av. Daily Volume 462,454

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 open-label trial to commence 1Q 2019.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016. Part A nearing completion, unlikely to continue through to Part B.
Epidiolex
Infantile spasms (IS)
Phase 2 trial did not meet endpoint
GWP42004
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Sativex
Cancer pain
Phase 2 data released February 21, 2018 - primary endpoint not met.
GWP42006 (CBDV)
Epilepsy
Phase 2 data released September 2015. Currently evaluating next steps
GWP42003
Schizophrenia
Approval announced June 25, 2018.
Epidiolex
Dravet Syndrome and Lennox-Gastaut syndrome
Phase 3 data due 2Q 2019.
Epidiolex
Tuberous Sclerosis Complex
Phase 3 trial planned for 4Q 2019.
Sativex
Spasticity due multiple sclerosis
GWP42006 (CBDV)
Autism
Phase 3 trial to commence 2Q 2019.
Epidiolex
Rett syndrome
Phase 3 data to be presented at AAN in late-breaker May 7, 2019. Abstract embargoed until May 3, 2019.
Epidiolex GWPCARE2
Dravet Syndrome